NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free ORTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.70▼$16.7050-Day Range$16.40▼$16.7052-Week Range$4.24▼$16.72VolumeN/AAverage Volume157,287 shsMarket Capitalization$380.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Orchard Therapeutics alerts: Email Address Orchard Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside49.7% Upside$25.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($4.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.48 out of 5 starsMedical Sector889th out of 938 stocksBiotechnology Industry23rd out of 26 stocks 3.2 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.00, Orchard Therapeutics has a forecasted upside of 49.7% from its current price of $16.70.Amount of Analyst CoverageOrchard Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ORTX. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 9 news articles for Orchard Therapeutics this week, compared to 9 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.90% of the stock of Orchard Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Orchard Therapeutics Stock (NASDAQ:ORTX)Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… ORTX Stock News HeadlinesMarch 27, 2024 | msn.comMeghan Markle’s American Riviera Orchard brand set to sell makeup, skincare and moreMarch 27, 2024 | msn.comThis spot at Orchard Road lets S’porean home-based bakers trial a physical store, rent-freeMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 27, 2024 | msn.comWhat is American Riviera Orchard? See what Meghan Markle's new brand is looking to sellMarch 26, 2024 | msn.comAmerican Riviera Orchard: Meghan Markle’s new California-inspired lifestyle brand explainedMarch 26, 2024 | msn.comThe Orchard West Theatre Dartford shows this SpringMarch 25, 2024 | msn.comMeghan Markle to sell makeup and body lotions through new brand American Riviera Orchard: reportMarch 23, 2024 | msn.comMeghan Markle’s American Riviera Orchard Is Missing 2 Elements of Success: ExpertMarch 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 22, 2024 | seekingalpha.comKyowa Kirin’s rare disease therapy becomes world’s most expensive drugMarch 21, 2024 | msn.comCelebrate spring at this upcoming event with Property Farms and McCallum's OrchardMarch 20, 2024 | bizjournals.comOrchard’s newly approved gene therapy is most expensive drug in historyMarch 20, 2024 | markets.businessinsider.comOrchard Therapeutics Announces Launch Plans For Lenmeldy - Quick FactsMarch 20, 2024 | globenewswire.comOrchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyMarch 19, 2024 | yahoo.comWhat is American Riviera Orchard? Meghan Markle's new lifestyle brand, explainedMarch 19, 2024 | finance.yahoo.comSpiritus Announces the First "Carbon Orchard" for Direct Air Capture, will Sequester 2 Megatons of Carbon Annually in WyomingMarch 18, 2024 | bizjournals.comFDA approves Orchard’s gene therapy for children with rare genetic diseaseMarch 18, 2024 | globenewswire.comOrchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.March 18, 2024 | reuters.comUS approves first gene therapy for rare genetic diseaseMarch 18, 2024 | msn.comLauren McConville hits century for Armagh as Orchard girls seal sport in National League finalMarch 17, 2024 | mirror.co.ukMeghan Markle's new lifestyle brand American Riviera Orchard has 'major red flags'March 16, 2024 | msn.comOrchard Lake St. Mary’s defeats North Farmington in MHSAA Division 1 boys basketball championshipMarch 16, 2024 | msn.comTom Izzo watches as Orchard Lake St. Mary's beats North Farmington in D-1 final, 63-52March 16, 2024 | msn.comMeghan Markle reportedly returning to Netflix with American Riviera Orchard lifestyle seriesMarch 16, 2024 | msn.comOL St. Mary's breezes to Div. 1 final, buoyed by 'one of the best shooters in the state'March 16, 2024 | msn.comWhat we know about Meghan’s new lifestyle brand American Riveria OrchardMarch 16, 2024 | msn.comMobile homes destroyed on parts of Orchard Island, Ohio, after violent tornadoSee More Headlines Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$34.00 Low Stock Price Target$16.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-333.90% Pretax Margin-334.54% Return on Equity-74.94% Return on Assets-33.51% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.98 Sales & Book Value Annual Sales$22.66 million Price / Sales16.77 Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book2.16Miscellaneous Outstanding Shares22,760,000Free Float22,099,000Market Cap$380.09 million OptionableOptionable Beta0.55 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Hubert Baburaj Gaspar M.D. (Age 61)Ph.D., CEO, Member of Scientific Advisory Board & Executive Director Comp: $901.42kMr. Frank Edward Thomas (Age 55)President & COO Comp: $763.95kDr. Nicoletta Loggia Ph.D.R.Ph., Chief Technical OfficerDr. Fulvio Mavilio Ph.D.Chief Scientific OfficerMs. Renee T. LeckHead of Investor RelationsBenjamin NavonDirector of Corporate CommunicationsMr. John CerioChief Human Resource OfficerMr. Robin KenselaarSenior VP & GM of EMEA Commercial OperationsMr. Braden ParkerChief Commercial OfficerDr. Leslie Meltzer Ph.D.Chief Medical OfficerMore ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPVoyager TherapeuticsNASDAQ:VYGRGlycoMimeticsNASDAQ:GLYCTheseus PharmaceuticalsNASDAQ:THRXTelomir PharmaceuticalsNASDAQ:TELOView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 137,520 shares on 3/1/2024Ownership: 0.604%Gamco Investors INC. ET ALBought 15,188 shares on 2/15/2024Ownership: 0.067%GTS Securities LLCBought 15,000 shares on 2/15/2024Ownership: 0.066%Vident Advisory LLCBought 11,270 shares on 2/15/2024Ownership: 0.050%Citadel Advisors LLCSold 1,200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions ORTX Stock Analysis - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for Orchard Therapeutics' stock. Their ORTX share price targets range from $16.00 to $34.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 74.94% and a negative net margin of 333.90%. When did Orchard Therapeutics' stock split? Orchard Therapeutics's stock reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? Orchard Therapeutics (ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Orchard Therapeutics' major shareholders? Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Blue Owl Capital Holdings LP (7.03%), Beryl Capital Management LLC (6.86%), Gabelli Funds LLC (0.99%), GABELLI & Co INVESTMENT ADVISERS INC. (0.85%), Goldman Sachs Group Inc. (0.60%) and Goldman Sachs Group Inc. (0.60%). Insiders that own company stock include Bobby Gaspar and Frank E Thomas. View institutional ownership trends. This page (NASDAQ:ORTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.